FDA compounder NDC directory
Browse every current FDA compounder source row, including records that do not contain a usable NDC.
Compounder NDC directory#
Every current compounder source row is browsable, including records whose FDA source did not provide a usable product, package, or lookup NDC. Browse the unified current auxiliary catalog. · Browse the complete captured source and snapshot history.
| Establishment | FEI | Product NDC | Package NDC | Brand | Nonproprietary name | Active ingredients | Period | Normalization | Source date |
|---|---|---|---|---|---|---|---|---|---|
| Hybrid Pharma | 079665742 | 26436-5502 | 26436-5502-3 | Estriol; Testosterone; Estradiol; Progesterone | .225 mg/1 g; .4 mg/1 g; .225 mg/1 g; 20 mg/1 g | 2024-2 | valid | 2026-10-15 | |
| Hybrid Pharma | 26436-5502 | 26436-5502-3 | Biest 0.45mg Progesterone 20mg Testosterone 0.4mg/gm | Biest 0.45mg Progesterone 20mg Testosterone 0.4mg/gm | .225 mg/1 g; .4 mg/1 g; .225 mg/1 g; 20 mg/1 g | 2024-2 | valid | 2026-09-18 | |
| Hybrid Pharma | 079665742 | 26436-5502 | 26436-5502-3 | Estriol; Testosterone; Estradiol; Progesterone | .225 mg/1 g; .4 mg/1 g; .225 mg/1 g; 20 mg/1 g | 2024-1 | valid | 2026-10-15 | |
| Hybrid Pharma | 079665742 | 26436-5502 | 26436-5502-3 | Estriol; Testosterone; Estradiol; Progesterone | .225 mg/1 g; .4 mg/1 g; .225 mg/1 g; 20 mg/1 g | 2023-2 | valid | 2026-10-15 | |
| Hybrid Pharma | 079665742 | 26436-5502 | 26436-5502-3 | Estriol; Testosterone; Estradiol; Progesterone | .225 mg/1 g; .4 mg/1 g; .225 mg/1 g; 20 mg/1 g | 2023-1 | valid | 2026-10-15 | |
| Hybrid Pharma | 079665742 | 26436-5502 | 26436-5502-3 | Estriol; Testosterone; Estradiol; Progesterone | .225 mg/1 g; .4 mg/1 g; .225 mg/1 g; 20 mg/1 g | 2021-1 | valid | 2026-10-15 |